GLP-1RAs have long been used to help individuals with type 2 diabetes manage blood sugar levels by mimicking the bodys natural hormones, but little is known about their impact on cardiovascular events
The scientific community has moved beyond viewing GLP-1 agonists solely as diabetes or obesity drugs, with substantial literature examining benefits across the metabolic disease spectrum [27, 28]
The SURPASS trial series (SURPASS 1-5) and SURMOUNT series provide granular data across diverse populations including patients with cardiovascular disease, chronic kidney disease, and diabetes making Tirzepatide the more data-rich compound for translational research applications
They regulate blood sugar and appetite by mimicking the action of the naturally occurring gut hormone GLP-1, a modulator of insulin secretion, glucagon, stomach emptying, and satiety signalling
The USA shows the highest listed rate because employer purchasing and direct-to-consumer access create a wide commercial pathway for virtual GLP-1 care